Skip to content

Effects of Functional Electrical Stimulation on the walking of people with Intermittent Claudication due to Peripheral Arterial Disease

Unveiling the effects of Functional Electrical Stimulation on the gait of individuals with Intermittent Claudication due to Peripheral Arterial Disease: a new perspective for rehabilitation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-523rphq
Enrollment
10
Registered
2026-07-22
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intermittent Claudication

Interventions

This is a single-blind, two-arm randomized crossover clinical trial. An eligible sample of 10 participants for each condition (with and without the Eleva® functional electrical stimulation orthosis) w
intervention conditions). On the first evaluation day (estimated duration of 2 hours), anthropometric measurements and demographic information will be collected first—a procedure performed only once.

Sponsors

Universidade de Santa Cruz do Sul - UNISC
Lead Sponsor
Pontifícia Universade Católica - PUCRS
Collaborator

Eligibility

Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients of both sexes and aged between 18 and 90 years; bilateral or unilateral peripheral arterial disease in Fontaine stage II with an ankle-brachial index equal to or less than 0.9 in the last 6 months; presenting with intermittent claudication, determined through the Edinburgh Questionnaire; clinically diagnosed femoropopliteal occlusive disease, with absence of thigh and buttock claudication; body mass index between 18.5 and 24.9 kg/m2 (normal weight), between 25.0 and 29.9 kg/m2 (overweight), and between 30.0 and 34.9 kg/m2 (class I obesity); absence of severe comorbidities that could interfere with the study

Exclusion criteria

Exclusion criteria: Acute coronary syndrome within 3 months of onset; chronic limb-threatening ischemia; presence of a pacemaker or other implanted devices; diagnosis of severe infections; significant pulmonary disease or heart failure; maximum walking time of less than 60 seconds or greater than 840 seconds in the modified Gardner treadmill test; presentation of contraindications to physical exercise testing, as described in current cardiac rehabilitation guidelines

Design outcomes

Primary

MeasureTime frame
An increase in maximum walking distance, obtained through the modified Gardner protocol, is expected with the use of the device, based on the observation of a variation of at least 10% between the control and intervention conditions;An increase in maximum walking distance, obtained through the 6-Minute Walk Test, is expected with the use of the device, based on the observation of a variation of at least 10% between the control and intervention conditions

Secondary

MeasureTime frame
An improvement in gait parameters, including cadence, gait speed, step length, stride length, stance time, swing time, and double-support phase, as assessed by accelerometry, is expected when using the device compared with the control condition;A relationship between static balance, as assessed by the Romberg test, and greater maximum walking distance, as assessed using the modified Gardner treadmill protocol, is expected;A relationship between functional independence, as assessed by the Functional Independence Measure, and greater maximum walking distance, as assessed by the Six-Minute Walk Test, is expected;A positive user comfort evaluation of the functional electrical stimulation orthosis is expected, as assessed using the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0), with participants achieving a score of at least 4 ("quite satisfied") on each questionnaire item

Countries

BR

Contacts

Public ContactDannuey Cardoso

Universidade de Santa Cruz do Sul - UNISC

dannuey@gmail.com+55(51)999648774

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Aug 10, 2026